Group
ClpP protease activator
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Other Targeted Agents |
| Mechanism of Action | ClpP protease activator |
| Drugs in group | Dordaviprone |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing (mitochondrial ClpP hyperactivation → OXPHOS collapse, ISR, TRAIL/DR5 death; RER >1) (Zhou et al., Oncotarget, 2025; Amoroso et al., Scientific Reports, 2021). Sensitization appears tumor-biased in preclinical models; theoretical normal-tissue adverse events is undefined.
The data above refer to patients treated with ClpP protease activator as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.